OCT 19, 2019 8:59 AM PDT

An alternative for immunotherapy-resistant cancer patients

A twist to traditional immunotherapies could help cancer patients’ immune systems better detect cancer cells, making this new system capable of targeting tumors that more conventional immunotherapies might miss. The research comes from scientists at Yale and was published recently in a study in Nature Immunology.

While immunotherapies have greatly broadened treatment options for many cancer patients by enabling their immune systems to fight cancer on their own, immunotherapy also has its own downfalls. Immunotherapy doesn’t work for all cancers or all individual cancer patients, and in fact, a common form of immunotherapy called checkpoint inhibitors are only effective in about one-third of patients. This is why continued investigation around the human immune system and its connection to cancer is crucial.

The researchers from Yale have created a new system that combines viral gene therapy and CRISPR gene-editing technology. "This is an entirely new form of immunotherapy," said senior author Sidi Chen, who is an assistant professor of genetics. The system is called Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI).

MAEGI works like a metal-detector for cancer cells, identifying their location and later tagging them for immune destruction. By doing so, the system is able to convert cold tumors to hot tumors (cold, meaning without immune cells, and hot meaning with immune cells). Additionally, explains Chen, "Once those cells are identified, the immune system immediately recognizes them if they show up in the future.” That allows for earlier future detection.

MAEGI offers hope for patients who do not respond to immunotherapies. Photo: Pixabay

The system was proven to work in mice with melanoma, triple-negative breast and pancreatic tumors. It was capable of either reducing or completely eradicating the tumors, no matter how close or far they were from the primary tumor.

The researchers hope that MAEGI will offer an alternative treatment option for those patients who are resistant to other immunotherapies. The team will be continuing their research to prepare for human clinical trials.

Sources: Yale, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 25, 2019
Cancer
NOV 25, 2019
Using AI to determine which patients are best suited for immunotherapy
A new study published in the journal Cancer Immunology Research suggests that we can use artificial intelligence to help determine which people with lung c...
NOV 29, 2019
Cancer
NOV 29, 2019
How flavonoids fight against colorectal cancer
New research published in the journal Cancers reports why flavonoids can aid in reducing the risk of colorectal cancer. Flavonoids are compounds found in f...
DEC 04, 2019
Cancer
DEC 04, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
JAN 15, 2020
Cell & Molecular Biology
JAN 15, 2020
Cell Division Research Reveals More About a Protein That's Elevated in Cancer
Cell division is a carefully regulated process, cancer is the result when it gets out of control....
JAN 20, 2020
Genetics & Genomics
JAN 20, 2020
Epigenetic Changes Make Breast Cancer Cells Drug Resistant
Researchers have found that changes in the structure of the genome in breast cancer cells can make them resistant to drug therapies....
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
Loading Comments...